Diabetic Retinopathy Market Size, Share, Growth, Analysis, 2034

(MENAFN- Straits Research) Diabetic Retinopathy Market Size & Growth Analysis

The global diabetic retinopathy market size was valued at USD 9.78 billion in 2025 and is projected to grow from USD 10.47 billion in 2026 to USD 18.13 billion by 2034, registering a CAGR of 7.1% during the forecast period from 2026 to 2034. North America dominated the diabetic retinopathy market with a market share of 38.5% in 2025.

Diabetic retinopathy is a diabetes-related illness that impacts the eyes. The condition results from harm to the blood vessels in the light-sensitive tissue located in the rear of the eye, referred to as the retina. Initially, diabetic retinopathy may be asymptomatic or only result in minor vision issues. However, in the long run, it can result in blindness. Diabetic retinopathy can occur in individuals with either type 1 or type 2 diabetes. The longer duration of diabetes and poor blood sugar control increases the likelihood of developing this eye problem.

Diabetic Retinopathy Market Key Takeaways Global Market Size & Growth

2025 Market Size: USD 9.78 Billion 2026 Market Size: USD 10.47 Billion 2034 Projected Market Size: USD 18.13 Billion Forecast Period: 2026–2034 Base Year: 2025 Market CAGR (2026–2034): 7.1%

Regional Insights

Largest Regional Market (2025): North America Asia Pacific Market Share (2025): 38.5% Fastest-Growing Region: Asia-Pacific Asia-Pacific CAGR (2026–2034): 9.38%

Segment Insights

By Type
Leading Segment: Non-proliferative Diabetic Retinopathy Market Share in 2025: 57.3%
By Treatment
Fastest-growing segment: Anti-VEGF Drug CAGR: 8.71% (2026-2034)

Download a Free Sample To learn more about this report,

Diabetic Retinopathy Market Trends Rising Global Diabetes Burden Increases Demand for Early Diabetic Retinopathy Screening

The growing prevalence of diabetes worldwide is significantly increasing the demand for diabetic retinopathy screening, diagnosis, and treatment services. Sedentary lifestyles, unhealthy dietary habits, obesity, and an ageing population have contributed to a steady rise in diabetes cases, resulting in a larger patient pool at risk of vision-threatening complications. As diabetic retinopathy often progresses without noticeable symptoms in its early stages, healthcare providers are placing greater emphasis on routine retinal examinations for early detection and timely intervention. Governments and healthcare organisations are also expanding diabetes awareness programmes and preventive eye care initiatives to reduce avoidable blindness. The growing adoption of regular screening programmes is expected to improve diagnosis rates and increase demand for advanced ophthalmic imaging devices and treatment options over the coming years.

In 2025, the International Diabetes Federation (IDF) reported that more than 589 million adults worldwide were living with diabetes, highlighting the urgent need for regular retinal screening and comprehensive diabetic eye care services to prevent vision loss.

Advancements in Retinal Imaging and Treatment Technologies Transform Patient Care

Continuous technological advancements are reshaping the diabetic retinopathy market by improving the accuracy of diagnosis and expanding treatment options. Innovations such as artificial intelligence (AI)-assisted retinal screening, ultra-widefield retinal imaging, optical coherence tomography (OCT), and longer-lasting anti-VEGF therapies are enabling earlier disease detection and more personalised treatment. These technologies help clinicians identify retinal damage at earlier stages while reducing diagnostic time and improving patient outcomes. In addition, healthcare providers are increasingly integrating digital ophthalmology solutions into routine diabetes management, particularly in remote and underserved regions where access to specialists is limited. As healthcare systems continue to invest in advanced ophthalmic technologies, the adoption of innovative diagnostic and therapeutic solutions is expected to accelerate worldwide.

In 2025, Topcon Healthcare expanded the deployment of its AI-enabled retinal screening solutions and cloud-based digital eye care platform, helping healthcare providers improve the early detection of diabetic retinopathy and streamline patient referrals for specialist treatment.

Diabetic Retinopathy Market Dynamics Market Drivers

AI-Powered Screening Improves Early Detection and Expands Screening Access

The integration of artificial intelligence (AI) into diabetic retinopathy screening is emerging as a significant growth driver for the Diabetic Retinopathy Market. AI-based systems can analyze retinal images rapidly and identify signs of diabetic retinopathy, helping healthcare providers detect disease at earlier stages and prioritize patients requiring specialist evaluation. These technologies can also support screening in primary care, community healthcare, and underserved areas where ophthalmologists may be limited. The growing availability of regulatory-approved AI screening platforms, combined with teleophthalmology and digital retinal imaging, is improving the scalability of screening programs and creating demand for advanced diagnostic solutions.

In July 2026, the U.S. FDA cleared iPredict-DR, an AI-based diabetic retinopathy detection device developed by iHealthscreen, for analyzing retinal images to identify referable diabetic retinopathy, adding another AI-enabled screening solution to the market.

Growing Ageing Population Increases the Risk of Diabetic Retinopathy

The rapidly expanding ageing population is significantly contributing to the growth of the diabetic retinopathy market. Older adults are more susceptible to chronic diseases such as type 2 diabetes, making them more vulnerable to diabetes-related eye disorders, including diabetic retinopathy. As life expectancy continues to improve globally, healthcare systems are witnessing a growing demand for ophthalmic examinations, retinal imaging, and long-term disease management. Governments and healthcare providers are also investing in preventive eye care services to address the increasing burden of age-related vision disorders. This demographic shift is expected to create sustained demand for advanced diagnostic technologies and effective treatment options for diabetic retinopathy in the coming years.

In 2025, the World Health Organization (WHO) highlighted that the global population aged 60 years and above had exceeded 1.1 billion, increasing the need for healthcare services focused on managing age-related conditions such as diabetic retinopathy.

Positive Factor	Estimated Impact (%)
Growing global diabetic population	+31%
Increasing ageing population requiring eye care	+25%
Rising adoption of routine retinal screening	+19%
Higher demand for advanced retinal imaging technologies	+15%
Expanding availability of diabetic retinopathy treatments	+10%

Market Restraints

Limited Awareness and Low Screening Rates Delay Early Diagnosis of Diabetic Retinopathy

Limited awareness of diabetic retinopathy remains a major challenge for the market, particularly in low- and middle-income countries where access to diabetes education and routine eye care is often limited. Many people living with diabetes are unaware that the disease can damage the retina long before noticeable vision problems develop. As a result, patients frequently delay comprehensive eye examinations until the condition has progressed to an advanced stage, reducing the effectiveness of available treatments. In addition, inadequate awareness among primary healthcare providers and unequal access to ophthalmology specialists can lead to delayed referrals and missed diagnoses. These factors increase the risk of irreversible vision loss while limiting the adoption of diagnostic imaging systems and treatment procedures. Strengthening public awareness campaigns, expanding diabetic eye screening programmes, and improving collaboration between diabetes specialists and ophthalmologists are essential to overcoming this restraint and improving patient outcomes.

In 2025, the International Agency for the Prevention of Blindness (IAPB) continued its Love Your Eyes campaign across multiple countries to encourage regular eye examinations and raise awareness of preventable vision loss caused by conditions such as diabetic retinopathy, highlighting the persistent global gap in public awareness and early screening.

Negative Factor	Estimated Impact (%)
Delayed diagnosis due to low public awareness	-29%
Reduced participation in routine diabetic eye screening	-24%
Late initiation of treatment leading to vision complications	-19%
Underdiagnosis and delayed referrals in primary healthcare	-16%
Lower adoption of advanced retinal diagnostic technologies	-12%

Market Opportunities

Advancements in AI-Powered Retinal Imaging and Digital Eye Care Create New Growth Opportunities

Continuous advancements in diagnostic imaging technologies and treatment modalities are creating significant growth opportunities in the diabetic retinopathy market. The integration of artificial intelligence (AI), machine learning (ML), cloud computing, and teleophthalmology is improving the speed and accuracy of retinal disease detection while enabling earlier intervention. AI-assisted retinal screening solutions can analyse retinal images within minutes, helping healthcare providers identify diabetic retinopathy before symptoms become severe. These technologies also support remote screening programmes, making quality eye care more accessible in underserved and rural communities. At the same time, improvements in optical coherence tomography (OCT), ultra-widefield imaging, and digital health platforms are enhancing disease monitoring and treatment planning. As healthcare systems continue to invest in digital ophthalmology and preventive eye care, the adoption of these advanced technologies is expected to accelerate worldwide.

In 2025, Topcon Healthcare expanded its AI-enabled Harmony digital health platform, allowing healthcare providers to integrate retinal imaging with cloud-based data management and streamline the early detection of diabetic retinopathy across multiple care settings.

Market Challenges

High Cost of Advanced Diagnostic Technologies and Limited Access to Specialist Eye Care Challenge Market Growth

The high cost of advanced retinal imaging systems and limited access to specialist eye care remain key challenges for the diabetic retinopathy market. Technologies such as optical coherence tomography (OCT), ultra-widefield retinal imaging, and AI-powered screening platforms require significant investment, making them less accessible for smaller hospitals and healthcare facilities, particularly in low- and middle-income countries. In addition, many rural and underserved regions face shortages of ophthalmologists and retinal specialists, resulting in delayed diagnosis and treatment. Although digital health and teleophthalmology are helping to bridge this gap, infrastructure limitations and inadequate reimbursement policies continue to slow widespread adoption. Addressing these challenges will require increased government funding, improved healthcare infrastructure, and broader deployment of affordable screening programmes to ensure timely access to diabetic eye care services.

In 2025, the World Health Organization (WHO) continued to highlight shortages in eye care services and unequal access to advanced ophthalmic equipment in many low-resource countries, emphasizing that workforce shortages and limited diagnostic infrastructure remain major barriers to preventing avoidable vision loss from conditions such as diabetic retinopathy.

Diabetic Retinopathy Market Segmentation By Type

Non-proliferative Diabetic Retinopathy Dominated the Market with a 57.3% Share in 2025

The non-proliferative diabetic retinopathy (NPDR) segment accounted for the largest share of the diabetic retinopathy market in 2025, capturing 57.3% of the global market. NPDR is the earliest and most common stage of diabetic retinopathy, making it the condition most frequently diagnosed during routine diabetic eye examinations.

Request Customization to receive a tailored report.

By Treatment

Anti-VEGF Drugs are Expected to Register the Highest CAGR of 8.71% During 2026–2034

The anti-VEGF drug segment is projected to witness the fastest growth during the forecast period, expanding at a CAGR of 8.71% from 2026 to 2034. Anti-VEGF therapies have become the preferred treatment for diabetic retinopathy and diabetic macular edema due to their ability to reduce retinal swelling, control abnormal blood vessel growth, and preserve vision.

Speak to an Analyst to discuss market opportunities.

Diabetic Retinopathy Market Regional Overview North America Diabetic Retinopathy Market Analysis

North America dominated the diabetic retinopathy market with a 38.5% share, valued at USD 3.77 billion in 2025, and is projected to grow at a CAGR of 7.84% during the forecast period. The region's leadership is supported by the high prevalence of diabetes, advanced healthcare infrastructure, and widespread availability of retinal screening and treatment services.

United States Diabetic Retinopathy Market Insights

The United States accounted for the largest share of the North American market, reaching USD 3.02 billion in 2025. The country benefits from a large diabetic population, extensive access to specialised ophthalmic care, and the rapid adoption of AI-assisted retinal imaging technologies.

Canada Diabetic Retinopathy Market Insights

Canada's diabetic retinopathy market was valued at USD 0.75 billion in 2025. Market growth is driven by rising diabetes prevalence, government-supported vision care initiatives, and improved access to retinal screening services.

Unlock Regional Insights to access country-level data, & regional trends.

Europe Diabetic Retinopathy Market Analysis

Europe accounted for 27.4% of the global diabetic retinopathy market, valued at USD 2.68 billion in 2025, and is expected to grow at a CAGR of 7.46% during the forecast period. Growth is supported by increasing awareness of diabetic eye diseases, strong public healthcare systems, and widespread implementation of national diabetic screening programmes.

Germany Diabetic Retinopathy Market Insights

Germany's diabetic retinopathy market reached USD 0.83 billion in 2025. The country's advanced healthcare infrastructure, high adoption of retinal imaging technologies, and strong presence of ophthalmology specialists continue to support market growth. Increasing healthcare expenditure and government initiatives promoting early diabetic eye examinations are further driving demand for diagnostic and treatment solutions.

United Kingdom Diabetic Retinopathy Market Insights

The United Kingdom recorded a market value of USD 0.61 billion in 2025. Growth is supported by the National Health Service (NHS) Diabetic Eye Screening Programme, which promotes regular retinal examinations for individuals with diabetes.

Asia-Pacific Diabetic Retinopathy Market Analysis

Asia-Pacific held a 23.6% share of the global diabetic retinopathy market, reaching USD 2.31 billion in 2025, and is projected to register the fastest CAGR of 9.38% during the forecast period. The region is experiencing rapid market expansion due to the rising prevalence of diabetes, growing ageing population, improving healthcare infrastructure, and increasing government investments in preventive healthcare.

Japan Diabetic Retinopathy Market Insights

Japan's diabetic retinopathy market was valued at USD 0.64 billion in 2025. The country's rapidly ageing population, advanced healthcare system, and strong adoption of innovative ophthalmic technologies continue to drive market growth. Increasing demand for early diagnosis and effective treatment options is encouraging hospitals and specialty eye clinics to adopt advanced retinal imaging and AI-supported screening solutions.

China Diabetic Retinopathy Market Insights

China accounted for the largest share of the Asia-Pacific market, reaching USD 1.08 billion in 2025. Market growth is driven by the country's large diabetic population, expanding healthcare infrastructure, and increasing government efforts to improve chronic disease management.

Middle East and Africa Diabetic Retinopathy Market Analysis

The Middle East and Africa accounted for 4.4% of the global diabetic retinopathy market, valued at USD 0.43 billion in 2025, and is expected to grow at a CAGR of 7.69% during the forecast period. Market growth is supported by increasing diabetes prevalence, improving healthcare infrastructure, and rising investments in specialised ophthalmic care.

United Arab Emirates Diabetic Retinopathy Market Insights

The United Arab Emirates diabetic retinopathy market reached USD 0.17 billion in 2025. Rising diabetes rates, strong healthcare investments, and increasing adoption of AI-powered diagnostic technologies are driving market expansion.

Latin America Diabetic Retinopathy Market Analysis

Latin America held a 6.1% share of the global diabetic retinopathy market, reaching USD 0.60 billion in 2025, and is projected to grow at a CAGR of 8.21% during the forecast period. Increasing diabetes prevalence, improving healthcare access, and expanding public health initiatives are supporting market growth across the region.

Brazil Diabetic Retinopathy Market Insights

Brazil accounted for the largest share of the Latin American market, with a value of USD 0.31 billion in 2025. Market growth is supported by the country's large diabetic population, improving access to ophthalmic care, and expanding public healthcare programmes focused on chronic disease management.

List of Key and Emerging Players in Diabetic Retinopathy Market

F. Hoffmann-La Roche Ltd. Novartis AG. Pfizer Inc. Bayer AG Isis Pharmaceuticals Inc. Valeant Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc. Abbott Laboratories Inc. Allergan Inc.

Key Industry Developments

May 2026: Bayer announced the acquisition of Perfuse Therapeutics in a deal worth up to USD 2.45 billion, strengthening its ophthalmology pipeline with PER-001, a Phase II therapy for diabetic retinopathy and glaucoma. April 2026: The U.S. FDA approved extended dosing intervals of up to 20 weeks for Regeneron's EYLEA HD (aflibercept 8 mg) for diabetic macular edema, reducing treatment burden for patients with diabetic retinal diseases. February 2025: Roche received U.S. FDA approval for Susvimo (ranibizumab injection) 100 mg/mL for diabetic retinopathy, expanding long-acting treatment options for retinal disease management. January 2025: Regeneron Pharmaceuticals acquired Oxular Limited, gaining access to its sustained-release retinal drug delivery technologies to strengthen its ophthalmology and diabetic retinopathy portfolio.

Report Scope

Market Metric	Details & Data (2025-2034)
Market Size in 2025	USD 9.78 Billion
Market Size in 2026	USD 10.47 Billion
Market Size in 2034	USD 18.13 Billion
CAGR	7.1% (2026-2034)
Base Year for Estimation	2025
Historical Data	2022-2024
Forecast Period	2026-2034
Study Period	2022-2034
Dominant Region	North America
Fastest Growing Region	Asia-Pacific
Key Market Players	F. Hoffmann-La Roche Ltd., Novartis AG., Pfizer Inc., Bayer AG, Isis Pharmaceuticals Inc.
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Type, By Treatment Type
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM
Countries Covered	US, Canada, UK, Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Singapore, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

MENAFN08092026004597010906ID1111634115